ArticleNPJ vaccines2020
Antibody responses to the RTS,S/AS01
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in NPJ vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Duration and association with protection of NANP-repeat-specific and C-terminus-specific anti-circumsporozoite protein IgG responses following RTS,S/AS01The Lancet. Infectious diseases · 2026Trial
- R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial.Frontiers in immunology · 2025Trial
- The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Trial
- Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial.Frontiers in immunology · 2025Article
- Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.Clinical pharmacology : advances and applications · 2025Review
- Effect of RTS,S/AS01NPJ vaccines · 2024Article
- IgG and IgM responses to the Plasmodium falciparum asexual stage antigens reflect respectively protection against malaria during pregnancy and infanthood.Malaria journal · 2024Article
- Cross-reactivity of rbioRxiv : the preprint server for biology · 2024Article
- Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection.JCI insight · 2022Article
- Article
- Understanding the role of serological and clinical data on assessing the dynamic of malaria transmission: a case study of Bagamoyo district, Tanzania.The Pan African medical journal · 2022Article
- ExploringFrontiers in immunology · 2022Article
- Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children.Malaria journal · 2021Article
- Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein.PLoS pathogens · 2021Article
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- In silico identification of novel open reading frames in Plasmodium falciparum oocyte and salivary gland sporozoites using proteogenomics framework.Malaria journal · 2021Article
- Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S/AS01e Malaria Vaccine Efficacy.Current epidemiology reports · 2021Review
- Anti-malarial humoral immunity: the long and short of it.Microbes and infectionReview
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
19 authors at 8 institutions in 7 countries.
Lina SanchezISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Marta VidalISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Chenjerai JairoceISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Ruth AguilarISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Itziar UbillosISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Inocencia CuambaCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Augusto J NhabombaCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Nana Aba WilliamsISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Núria Díez-PadrisaISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
David CavanaghInstitute of Immunology & Infection Research and Centre for Immunity, Infection & Evolution, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, King's Buildings, Edinburgh, UK.
Evelina AngovU.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD USA.
Ross L CoppelInfection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC Australia.
Deepak GaurMalaria Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
James G BeesonBurnet Institute, Melbourne, VIC Australia.
Sheetij DuttaU.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD USA.
Pedro AideCentro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.ORCID 0000-0002-2379-6529
Joseph J CampoUnivLyon, Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
Gemma Moncunill *ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.
Carlota Dobaño *ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Catalonia Spain.ORCID 0000-0002-6751-4060
Manhiça Health Research Centre · MZBarcelona Institute for Global Health · ESUniversité Claude Bernard Lyon 1 · FRWalter Reed Army Institute of Research · USBurnet Institute · AUCentre for Immunity, Infection and Evolution · GBDiscovery Institute · USJawaharlal Nehru University · IN
Funding
Understanding RTS,S malaria vaccine-induced protection through integrated analysiR01AI095789 · NIAID · BARCELONA INTERNATIONAL HEALTH RES CTR · PI DOBANO, CARLOTA · 2012 to 2016
$3.2MMinistry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CD010/00156NIAID NIH HHS R01 AI095789
Abstract
The RTS,S/AS01
Indexed as
Adaptive immunityMalariaVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.